Síndrome das pernas inquietas com herança autossômica dominante piorada pelo uso de mirtazapina: relato de caso

Teive, Hélio A.G.; Quadros, Anibal de; Barros, Felipe Cabral; Werneck, Lineü Cesar

doi:10.1590/s0004-282x2002000600027

Cited by 20 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Except for an Asian 2 and a Chilean study 3 , there are no data available about prevalence in non-white population 4 . Many other conditions can cause secondary RLS (for example, psychoactive drugs 5 ), possibly with different pathophysiological mechanisms. The pathophysiology of RLS in chronic renal failure (CRF) is not established.…”

mentioning

confidence: 99%

Restless legs syndrome in patients on chronic hemodialysis in a Brazilian city: frequency, biochemical findings and comorbidities

Filho

Gorini

Purysko

et al. 2003

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-Objective: To evaluate the frequency of restless legs syndrome (RLS) in patients with chronic renal failure (CRF) in Petrópolis, Brazil, and investigate associations between the syndrome and: demographic characteristics, biochemical variables and comorbidities. Method: A cross-sectional study in which we interviewed 176 patients on dialytic therapy based on criteria elaborated by the International Restless Legs Syndrome Study Group, and compared data of patients with and without RLS. Results: The frequency was 14.8 %. There were no significant differences between the two groups in demographic and biochemical variables investigated (iron, creatinine, intact parathyroid hormone, hemoglobin, calcium, phosphate). We found no association between RLS and the most common comorbidities, except for chronic glomerulonephritis (CGN) (OR = 3.84, p < 0.01). Conclusion: In the studied population RLS is a common disorder, and is not associated with the investigated biochemical abnormalities. A higher frequency of RLS in subjects with CGN is a finding that needs further investigation.KEY WORDS: restless legs syndrome, chronic renal failure, chronic glomerulonephritis.Síndrome das pernas inquietas em pacientes em programa de hemodiálise em P índrome das pernas inquietas em pacientes em programa de hemodiálise em P índrome das pernas inquietas em pacientes em programa de hemodiálise em P índrome das pernas inquietas em pacientes em programa de hemodiálise em P índrome das pernas inquietas em pacientes em programa de hemodiálise em Petrópolis, RJ: frequência, etrópolis, RJ: frequência, etrópolis, RJ: frequência, etrópolis, RJ: frequência, etrópolis, RJ: frequência, aspectos laboratoriais e comorbidades. aspectos laboratoriais e comorbidades. aspectos laboratoriais e comorbidades. aspectos laboratoriais e comorbidades. aspectos laboratoriais e comorbidades. RESUMO -Objetivo: Determinar a frequência de síndrome das pernas inquietas (SPI) em pacientes com insuficiência renal crônica (IRC) em Petrópolis, Brasil, e investigar associação entre a síndrome e: dados demográficos, achados bioquímicos e comorbidades. Método: Estudo transversal no qual entrevistamos 176 pacientes em terapia dialítica a partir de critérios definidos pelo International Restless Legs Syndrome Study Group, e comparamos dados de pacientes com e sem SPI. Resultado: A frequência foi 14,8 %. Não houve diferença significativa entre os 2 grupos nas variáveis demográficas e bioquímicas (ferro, cretinina, paratormônio, hemoglobina, cálcio, fósforo) investigadas. Não houve associação entre SPI e as principais comorbidades, exceto glomerulonefrite crônica (GNC) (OR = 3,84, p < 0,01). Conclusão: SPI é condição comum na população estudada, e não é associada com as alterações bioquímicas investigadas. O achado de maior frequência de SPI em pacientes com GNC merece investigações mais detalhadas. The frequency of restless legs syndrome (RLS) is higher in patients with end-stage renal disease than in the general population, and previous studies have reported it to vary...

show abstract

mentioning

confidence: 99%

Restless legs syndrome in patients on chronic hemodialysis in a Brazilian city: frequency, biochemical findings and comorbidities

Filho

Gorini

Purysko

et al. 2003

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…For 1990 and 2019, a total of 52 reports containing 179 individuals that developed a MD associated with MTZ were identified from 20 different countries [ Table 1 ] [ 10 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 ]. 103 individuals were from European countries, 49 Asian, 17 Australian, 8 North American, and 2 South American.…”

Section: R Esultsmentioning

confidence: 99%

Mirtazapine-associated movement disorders: A literature review

Rissardo

Caprara

2020

Tzu Chi Med J

View full text Add to dashboard Cite

Mirtazapine (MTZ) is an atypical antidepressant approved by the FDA, which mechanism of action involves the antagonism of alpha-2, H1, 5-HT2A, 5-HT2C, and 5-HT3 receptors. In this context, the aim of this literature review is to evaluate the clinical epidemiological profile, pathological mechanisms, and management of MTZ-associated movement disorders (MDs). Relevant reports of six databases were identified and assessed by two reviewers without language restriction. Fifty-two reports containing 179 cases from 20 countries were assessed. The mean age was 57 year (range, 17–85). The majority of the individuals were female (60%) and of European origin. The mean time from MTZ start to symptom onset was 7.54 days; the time from management to MD improvement was within one week in 82.60% of the individuals. The MDs associated with MTZ were 69 restless legs syndrome (RLS), 35 tremors, 10 akathisia (AKT), 9 periodic limb MD, 6 dystonia, 4 rapid eye movement sleep behavior disorders, 3 dyskinesia, 2 parkinsonism, and 1 tic, and in the group not clearly identified, 18 restlessness, 15 hyperkinesis, and 1 extrapyramidal symptom. In the literature, the majority of the reports lack important information about the neurological examination. The management should be the MTZ withdrawal, except in RLS that other options are possible. In AKT, the MTZ should not be rechallenge, and if available, the prescription of a benzodiazepine may reduce recovery time.

show abstract

“…These include several classes of antidepressants, including tricylic antidepressants (TCAs), 1-3 such as imipramine 4 and selective serotonin or norepinephrine reuptake inhibitors (SSRIs, SNRIs), 5-7 such as citalopram, 8 escitalopram, 9 fluoxetine, 10-12 sertraline, 13, 14 paroxetine, 15, 16 trazodone, 17, 18 venlafaxine, 19 and mirtazapine 12, 20-26 ; along with neuroleptics that have significant dopaminergic blockade 27-30 such as olanzapine, 31-34 risperidone, 35 and quetiapine, 15, 36 in addition to lithium. 1, 37, 38 Antihistamines operating on the H1 receptor, 39, 40 and selected anti-emetics with dopamine antagonism such as metoclopramide 41 and prochlorperazine, 42 have also been associated with RLS.…”

Section: Introductionmentioning

confidence: 99%

Medications associated with restless legs syndrome: a case–control study in the US Renal Data System (USRDS)

2014

View full text Add to dashboard Cite

Objective To determine the association between the usage of four classes of “at risk” medications (antidepressants, neuroleptics, antihistamines, and anti-emetics with dopamine blockade) and restless legs syndrome (RLS) in dialysis patients within the United States Renal Data System (USRDS). Methods This was a case-control design within a national (United States) patient registry of all patients with End Stage Renal Disease (ESRD) in the USRDS anytime during the period of October 1, 2006 and December 31, 2010, inclusive. A total of 16,165 ESRD patients (3,234 Cases; 12,931 age-, sex-, and race-matched Controls) were studied. Results All four classes of “at risk” medications see widespread use among patients in the USRDS. All were associated with increased odds of a RLS diagnosis (range of Odds Ratios: 1.47 to 2.28, all p < .0001) during the period of observation. Results were unchanged when controlling for time on hemodialysis. Usage of more than one class of medication increased the odds for having RLS. Conclusions ESRD patients often receive medication intended for relief of conditions associated with their disease, such as depression and psychological issues, pruritis and gastroparesis, however such medications may increase risk for RLS. Given the high prevalence of RLS in ESRD patients, these medications should only be used when their benefits clearly outweigh the risk of development of the troubling and distressing symptoms of restless legs syndrome.

show abstract

Síndrome das pernas inquietas com herança autossômica dominante piorada pelo uso de mirtazapina: relato de caso

Cited by 20 publications

References 22 publications

Restless legs syndrome in patients on chronic hemodialysis in a Brazilian city: frequency, biochemical findings and comorbidities

Restless legs syndrome in patients on chronic hemodialysis in a Brazilian city: frequency, biochemical findings and comorbidities

Mirtazapine-associated movement disorders: A literature review

Medications associated with restless legs syndrome: a case–control study in the US Renal Data System (USRDS)

Contact Info

Product

Resources

About